BioLineRx (BLRX) 6-K BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2024

Commission file number: 001-35223

BioLineRx Ltd.

(Translation of registrant’s name into English)

2 HaMa’ayan Street

Modi’in 7177871, Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒          Form 40-F ☐

On May 28, 2024, the Registrant issued a press release announcing its financial results for the three months ended March 31, 2024. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of March 31, 2024 and for the three months then ended. Attached hereto are the following exhibits:

Exhibit 1: Registrant’s press release dated May 28, 2024;

Exhibit 2: Registrant’s condensed consolidated interim financial statements as of March 31, 2024 and for the three months then ended; and

Exhibit 3: Registrant’s operating and financial review as of March 31, 2024 and for the three months then ended.

This Form 6-K, the text under the heading “Financial Results for the Quarter Ended March 31, 2024” in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioLineRx Ltd.
By:	/s/ Philip A. Serlin
	Philip A. Serlin
	Chief Executive Officer

Dated: May 28, 2024